The co-existence of ER and HER2 signaling pathways within heterogeneous tumor populations creates a complex therapeutic challenge, as differential pathway activation across cellular subpopulations often leads to incomplete treatment response and disease relapse [54]. This evidence concerns the gene ESR1 and neoplasm.